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Abstract
Extracorporeal circulation (ECC) and hypothermia are used to maintain stable circulatory parameters and improve the
ischemia tolerance of patients in cardiac surgery. However, ECC and hypothermia induce activation mechanisms in platelets
and leukocytes, which are mediated by the platelet agonist ADP and the phosphoinositide-3-kinase (PI3K) p110b. Under
clinical conditions these processes are associated with life-threatening complications including thromboembolism and
inflammation. This study analyzes effects of ADP receptor P2Y12 and P2Y1 blockade and PI3K p110b inhibition on platelets
and granulocytes during hypothermic ECC. Human blood was treated with the P2Y12 antagonist 2-MeSAMP, the P2Y1
antagonist MRS2179, the PI3K p110b inhibitor TGX-221, combinations thereof, or PBS and propylene glycol (controls). Under
static in vitro conditions a concentration-dependent effect regarding the inhibition of ADP-induced platelet activation was
found using 2-MeSAMP or TGX-221. Further inhibition of ADP-mediated effects was achieved with MRS2179. Next, blood
was circulated in an ex vivo ECC model at 28uC for 30 minutes and various platelet and granulocyte markers were
investigated using flow cytometry, ELISA and platelet count analysis. GPIIb/IIIa activation induced by hypothermic ECC was
inhibited using TGX-221 alone or in combination with P2Y blockers (p,0.05), while no effect of hypothermic ECC or
antiplatelet agents on GPIIb/IIIa and GPIba expression and von Willebrand factor binding was observed. Sole P2Y and PI3K
blockade or a combination thereof inhibited P-selectin expression on platelets and platelet-derived microparticles during
hypothermic ECC (p,0.05). P2Y blockade alone or combined with TGX-221 prevented ECC-induced platelet-granulocyte
aggregate formation (p,0.05). Platelet adhesion to the ECC surface, platelet loss and Mac-1 expression on granulocytes
were inhibited by combined P2Y and PI3K blockade (p,0.05). Combined blockade of P2Y12, P2Y1 and PI3K p110b completely
inhibits hypothermic ECC-induced activation processes. This novel finding warrants further studies and the development of
suitable pharmacological agents to decrease ECC- and hypothermia-associated complications in clinical applications.
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Introduction
Under physiological conditions, platelets play a fundamental
role in hemostasis, prevention of blood loss, and healing of
vascular injury. However, dysfunctional platelets can cause serious
problems like abnormal thrombus formation and consecutive
vessel occlusion as well as severe bleeding complications, which are
all feared side effects of extracorporeal circulation (ECC) [1,2].
ECC is employed in many cardiac surgical procedures to ensure
gas exchange and to maintain stable circulatory parameters of the
patient. In addition, hypothermia ranging between 28uC and
32uC is routinely employed during cardiac operations in addition
to ECC to increase the ischemia tolerance of the patient. Shear
stress, contact of blood with the artificial surfaces of the ECC
circuit as well as hypothermia are all known to be associated with
platelet activation, which results in disturbed platelet function and
associated complications [1,3,4]. Furthermore, activated platelets
can trigger an inflammatory response through interactions with
leukocytes [5]. These platelet-leukocyte interactions are mainly
mediated by binding of the platelet surface receptor P-selectin to
its counter receptor P-selectin glycoprotein ligand-1 (PSGL-1) on
leukocytes. Subsequently, upregulation and activation of the Mac-
1 receptor (CD11b/CD18) on leukocytes is induced as a result of
the P-selectin-PSGL-1 interaction [5,6]. Furthermore, it has been
shown that CD40 ligand, which is shed from platelets upon
activation, also promotes Mac-1 upregulation [7].
Inhibition of platelet activation is a possible approach to inhibit
platelet dysfunction and related detrimental effects during ECC.
One pharmacological strategy to inhibit platelet activation is
blockade of the platelet ADP receptors P2Y12 and P2Y1 [8,9].
We have recently shown that ADP plays a major role in ECC-
and hypothermia-induced platelet activation [10]. Inhibition of
platelet granule release could be achieved during hypothermic
ECC via P2Y12 blockade [11]. Nevertheless, despite effective
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platelet protection by P2Y12 blockade, still higher degrees of
platelet activation compared to baseline values were observed.
Furthermore, platelet adhesion to the ECC surface and therefore
platelet loss could not be prevented. Consequently, in addition to
ADP other factors obviously activate platelets during ECC. In this
regard, shear-induced activation of platelets is another important
factor during ECC [4,12]. Shear triggers a signaling pathway,
which includes activation of the class Ia phosphoinositide-3-kinase
(PI3Ks) p110b isoform. This results in activation of the platelet
fibrinogen receptor GPIIb/IIIa and platelet aggregate formation
[13,14,15,16].
On the basis of these data, we hypothesize that substantial
platelet protection during ECC and hypothermia may be achieved
by combined inhibition of P2Y12, P2Y1 and PI3K p110b. To prove
this, we first defined effective doses of the P2Y12 antagonist 2-
MeSAMP and the PI3K p110b blocker TGX-221 to achieve
substantial inhibition of platelet activation in vitro. Afterwards, the
effect of single and combined blockade of ADP receptors and
PI3K p110b on platelet activation, platelet adhesion to the ECC
surface, their interaction with granulocytes as well as subsequent
granulocyte activation was investigated in human whole blood
employing an ex vivo ECC model at hypothermia (28uC).
Results
Concentration-dependent Inhibition of ADP-induced P-
selectin Expression using 2-MeSAMP and TGX-221 and
the Effect of MRS2179
Treatment of whole blood with different concentrations of 2-
MeSAMP (10 and 100 mM) showed that ADP-induced (final ADP
concentration: 20 mM) P-selectin expression is more potently
inhibited with higher antagonist concentrations (Figure 1A). The
addition of MRS2179 (100 mM) in the 2-MeSAMP-treated group
further decreased the expression of platelet P-selectin expression
upon ADP activation (Figure 1A).
Furthermore, a TGX-221 concentration of 2.2 mM is more
potently inhibiting ADP-induced P-selectin expression in human
whole blood, when compared to a TGX-221 concentration of
0.5 mM (Figure 1B).
PI3K p110b Inhibition Alone or in Combination with ADP
Receptor Blockade has no Effect on Expression Levels of
GPIIb/IIIa and GPIba as Well as on vWF Binding of
Platelets, but Reduces GPIIb/IIIa Activation during
Hypothermic ECC
Platelet activation is accompanied by a conformational change
of the platelet GPIIb/IIIa receptor into a high-affinity conforma-
tion, which enables binding of ligands including fibrinogen and
vWF [19]. Using specific antibodies we analyzed (1) the general
expression of GPIIb/IIIa on the platelet surface and (2) the
GPIIb/IIIa activation state. Basic GPIIb/IIIa expression was
neither influenced by hypothermic ECC nor by antiplatelet agents
(Figure 2A), while hypothermic ECC induced a significant in-
crease in GPIIb/IIIa activation in controls (p,0.01; Figure 2B).
This effect was inhibited by PI3K p110b inhibition using TGX-
221 alone (p,0.05) and more profoundly by PI3K p110b
inhibition combined with P2Y blockade (2-MeSAMP and
MRS2179; p,0.001).
The GPIba receptor is involved in mediating primary platelet
adhesion via binding to its ligand vWF [19]. Upon platelet
activation GPIba surface expression is decreased due to down-
regulation [20] or receptor shedding [21,22]. Regarding the
expression of the GPIba receptor on platelets as well as vWF
binding to platelets in our experiments, no effect of either
hypothermic ECC or P2Y and PI3K p110b inhibition was
observed (Figure 2C and D). It has previously been described
that the platelet agonist ADP decreases GPIba surface expression
on platelets [20,23,24]. This finding was confirmed in our
experiments and indicated intact platelet reactivity before and
after hypothermic ECC in the PBS group (Figure 2C).
In addition, vWF binding was investigated on ADP-activated
platelets before and after hypothermic ECC in the PBS group.
ADP induced a significant increase in vWF binding at both
timepoints (Figure 2D). Regarding the fact that GPIba surface
expression was downregulated at the same time, this finding is
Figure 1. Concentration-dependent inhibition of ADP-induced P-selectin expression using 2-MeSAMP and TGX-221. Heparinized
human whole blood (n = 4) was treated for 5 minutes at 37uC with (A) PBS as control, 2-MeSAMP (10 and 100 mM; ‘‘2-MeS’’) or a combination (100 mM
each) of 2-MeSAMP and MRS2179 and (B) propylene glycol (‘‘PG’’) as control or TGX-221 (0.5 or 2.2 mM; ‘‘TGX’’). Afterwards platelets were activated
using ADP (final concentration: 20 mM) and the percentage of P-selectin expressing platelets under a pre-set histogram marker was analyzed in flow
cytometry using an anti-P-selectin mAb. Data are given as means and SD.
doi:10.1371/journal.pone.0038455.g001
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most likely due to binding of vWF to GPIIb/IIIa. In this regard, it
has previously been described that platelets have other binding
sites for vWF then GPIba [25] and that vWF is a ligand of the
GPIIb/IIIa receptor [19,26].
Hypothermic ECC-induced P-selectin Expression on
Platelets and Platelet Microparticles is Profoundly
Inhibited by P2Y and PI3K p110b Inhibitors
As an indicator for a-granule release and platelet activation, P-
selectin expression on the surface of platelets and platelet-derived
microparticles was measured before and after hypothermic ECC.
Single platelets and PMPs were identified according to their size
and granularity (Figure 3A). As a positive control P-selectin
expression on ADP-stimulated platelets was measured to confirm
platelet reactivity before and after circulation in the control group
(Figure 3B).
P-selectin expression significantly increased during hypothermic
ECC in controls (p,0.05, Figure 3C). Both P2Y blockade and
PI3K p110b inhibition alone as well as combined inhibition of
ADP receptors and PI3K p110b completely inhibited this
phenomenon (p,0.05).
PMPs, which express typical platelet surface receptors including
P-selectin, are released from platelets upon activation [3,27,28]. In
our experiments the total number of PMPs was not affected by
hypothermic ECC or antiplatelet agents (data not shown).
Nevertheless, P-selectin expression on PMPs was significantly
increased by hypothermic ECC (p,0.001; Figure 3D). P2Y
receptor blockade, PI3K p110b inhibition as well as the
combination of P2Y receptor and PI3K p110b inhibition
significantly reduced P-selectin expression on PMPs (p,0.05).
Figure 2. GPIIb/IIIa and GPIba expression as well as vWF binding are not influenced by ex vivo hypothermic ECC and antiplatelet
agents, while platelet PI3K p110b inhibition alone or in combination with P2Y12/P2Y1 receptor blockade reduce GPIIb/IIIa activation
induced by hypothermic ECC. Human blood was left untreated (‘‘before circ.’’) or treated ex vivo with PBS (control), a combination of 2-MeSAMP
and MRS2179 to block P2Y receptors (100 mM each; ‘‘P2Y block’’), propylene glycol (‘‘PG’’, control), TGX-221 to inhibit PI3K p110b (2.2 mM; ‘‘TGX’’) or
a combination of 2-MeSAMP, MRS2179 (100 mM each) and TGX-221 (2.2 mM; ‘‘P2Y block + TGX’’). All treated samples were circulated in an ECC model
for 30 minutes at 28uC. Expression of GPIIb (A; n = 4), activated GPIIb/IIIa (B; n = 6), GPIba (C; n = 6) as well as vWF binding (D; n = 4) were evaluated in
flow cytometry using specific antibodies. ADP stimulation (20 mM) before and after hypothermic ECC was performed as positive control for GPIba
expression (C) and vWF binding (D) in the PBS group. Geometric mean fluorescence values of fluorescently labeled antibodies are given in diagrams
as means and SD; not normally distributed data were analyzed using a non-parametrical test (Friedman test with Dunn`s multiple comparison test; A,
D); normally distributed data (B, C) were compared using RM-ANOVA with Bonferroni’s multiple comparison test; *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0038455.g002
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Effects of Hypothermic ECC, P2Y Blockade and PI3K
p110b Inhibition on Platelet-ECC Adhesion, Platelet-
granulocyte Aggregate Formation and Platelet Loss
Hypothermic ECC induced a significant increase in platelet
adhesion to the artificial ECC surface in controls (p,0.001;
Figure 4A). This was only prevented by a combination of P2Y
blockade and PI3K p110b inhibition (p,0.05), but not by P2Y
blockade or PI3K p110b inhibition alone.
Interaction of activated platelets with leukocytes plays a pivotal
role in ECC-related pro-inflammatory complications [1,29]. We
evaluated the formation of platelet-granulocyte aggregates during
hypothermic ECC ex vivo. A significant increase in aggregate
formation was found after 30 minutes of circulation at 28uC in
controls (p,0.01; Figure 4B). This phenomenon was significantly
inhibited by P2Y blockade alone (p,0.05) and by combined
treatment with P2Y and PI3K p110b blockers (p,0.05).
A significant decrease of platelet counts was observed during
hypothermic ECC (p,0.01; Figure 4C). The combination of P2Y
blockers and PI3K p110b inhibitor significantly prevented
hypothermic ECC-induced platelet loss (p,0.05).
P2Y Blockade in Combination with a PI3K p110b Inhibitor
Prevents Upregulation of the Mac-1 Receptor on
Granulocytes
Interaction of activated platelets with leukocytes triggers the
upregulation of the Mac-1 receptor on leukocytes. Mac-1 mediates
leukocyte adhesion and migration as well as interaction and
binding of leukocytes and platelets [30]. To evaluate granulocyte
activation, we measured surface CD11b expression on granulo-
cytes. Hypothermic ECC induced a profound increase in CD11b
expression on granulocytes in controls (p,0.05; Figure 5). This
was significantly decreased by P2Y blockade in combination with
PI3K p110b inhibition (p,0.001). P2Y and PI3K p110b in-
hibition alone had no effect on hypothermic ECC-induced CD11b
expression on granulocytes.
Figure 3. Blockade of P2Y12 and P2Y1 as well as PI3K p110b inhibition profoundly inhibits hypothermic ECC-induced P-selectin
expression on platelets and platelet microparticles. Prior to (‘‘before circ.’’) and after hypothermic ECC (28uC, 30 minutes) flow cytometric
analysis of P-selectin expression on platelets and PMPs was performed in groups treated with either PBS as control, 2-MeSAMP and MRS2179 (100 mM
each; ‘‘P2Y block’’), propylene glycol (‘‘PG’’) as control, TGX-221 to inhibit PI3K p110b (2.2 mM; ‘‘TGX’’) or a combination of 2-MeSAMP and MRS2179
(100 mM each) as well as TGX-221 (2.2 mM; ‘‘P2Y block + TGX’’). Representative dot plot indicating the identification of PMPs, single platelets and
aggregates according to their size and granularity (A). Representative histogram overlay including a marker to identify percentages of P-selectin
expressing platelets before circulation without additional stimulation (grey filled), before circulation with addition of ADP (20 mM; grey solid line) as
well as 30 minutes after hypothermic ECC (black solid line) (B). Percentages of platelets (C) and PMPs (D) expressing P-selectin are depicted. Data in
(C) and (D) are given as means (n = 6) and SD; groups were compared using RM-ANOVA with Bonferroni’s multiple comparison test; *p,0.05;
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0038455.g003
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Discussion
In this study, we investigate the effects of ADP receptor
blockade combined with PI3K p110b inhibition on platelets and
granulocytes in an ex vivo model simulating hypothermic ECC. In
general, our current findings confirm previously reported effects of
hypothermic ECC on platelet activation, which lead to numerous
responses in platelets like: platelet adhesion to the ECC surface,
granule release associated with upregulation of P-selectin on
platelets and PMPs, activation of GPIIb/IIIa and subsequent
interaction of platelets and granulocytes as well as granulocyte
activation (Figure 6) [1,2,12,31,32,33,34]. In our current study,
GPIba and GPIIb/IIIa expression levels as well as vWF binding
to platelets were unaffected by hypothermic ECC. Hypothermic
ECC did also not result in increased PMP numbers, but in an
increase of P-selectin expression on PMPs and single platelets.
This contributes to explain the increase in platelet-granulocyte
aggregate formation and upregulation of Mac-1 expression on
granulocytes as observed in our experiments, since P-selectin
expressing platelets and PMPs can mediate binding and consec-
utive activation of platelets and leukocytes [35]. Furthermore, the
observed loss of platelet counts after hypothermic ECC can be
explained by the fact that aggregate formation as well as platelet
adhesion to the ECC surface occurred during hypothermic ECC.
Based on these data and previous findings [3,10,36], a routine
strategy for platelet protection during ECC and hypothermia is
warranted and could be very beneficial for many patients in
clinical settings where ECC and hypothermia are employed.
In patients with coronary disease platelet inhibition is routinely
performed with ADP receptor P2Y12 blockers including the
thienopyridines clopidogrel and prasugrel [37,38]. We have
recently reported that administration of cangrelor, a reversible
non-thienopyridine P2Y12 receptor blocker with short plasma
half-life (3–6 minutes) [39] effectively reduces platelet granule
release, platelet-granulocyte binding, and platelet loss during
hypothermic ECC [11]. Furthermore, according to its short half-
Figure 4. Effects of hypothermic ECC and platelet inhibitor treatment on platelet adhesion to the ECC surface, platelet-granulocyte
aggregate formation and platelet counts. Human blood samples were either left untreated or treated with PBS (control group), a combination
of 2-MeSAMP and MRS2179 (100 mM each; ‘‘P2Y block’’), propylene glycol (‘‘PG’’, control group), TGX-221 (2.2 mM; ‘‘TGX’’) or a combination of 2-
MeSAMP, MRS2179 and TGX-221 (‘‘P2Y block + TGX’’). Blood, which was treated accordingly, was circulated in an ex vivo ECC model at 28uC for
30 minutes. A specific ELISA method was employed to detect platelet adhesion to the ECC surface (A; n = 6). Platelet-granulocyte aggregate
formation was measured in flow cytometry before circulation (‘‘before circ.’’) and after circulation in all treatment groups (B; n = 4) according to the
fluorescence of an anti-CD15-PE antibody on aggregates (aggregate region in figure 3A) under a pre-set histogram marker. Platelet counts were
measured in all samples (C; n = 6). Data are given as means and SD; normally distributed data were compared using RM-ANOVA with Bonferroni’s
multiple comparison test (A, B); not normally distributed data were analyzed using a non-parametrical test (Friedman test with Dunn`s multiple
comparison test; C); *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0038455.g004
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life administration of cangrelor only during ECC results in rapid
recovery of platelet function after ECC and is not associated with
blood loss. Nevertheless, cangrelor had no inhibitory effects on
platelet-ECC binding and no sustainable effect on GPIIb/IIIa
activation [11]. In the setting of normothermic ex vivo ECC
(37uC), platelet-ECC adhesion as well as platelet-platelet and
platelet-granulocyte aggregation can be very effectively decreased
with the PI3K p110b inhibitor TGX-221 [4]. In addition,
further inhibition of ADP-mediated effects may be achieved by
blocking not only P2Y12, but also P2Y1 on platelets. Therefore,
the aim of our current study was to combine full platelet ADP
receptor blockade with inhibition of shear-induced platelet
activation to completely inhibit platelet activation during ECC
and hypothermia.
At first, we employed a combination of experimental P2Y12 and
P2Y1 blockers to protect platelets during hypothermic ECC. The
P2Y1 receptor has been suggested as a crucial target for inhibition
of ADP-mediated effects, since P2Y1 activation is necessary for full
platelet aggregation [8]. Nevertheless, until today, no P2Y1
antagonist for clinical applications has been developed [40,41].
We therefore used the experimental and reversible P2Y1 antag-
onist MRS2179, which has been shown to substantially inhibit
ADP-induced platelet aggregation [42]. Furthermore, 2-Me-
SAMP, a specific inhibitor of the platelet P2Y12 receptor
[43,44], was used in the current study, because previous ex vivo
experiments as well as our current in vitro experiments showed
substantial and specific P2Y12 blockade to a similar extent then the
effect observed with cangrelor [10,11].
Our results show, that combined P2Y12 and P2Y1 blockade
results in significant inhibition of P-selectin expression on platelets
and PMPs as well as a reduction in platelet-granulocyte
aggregates. Nevertheless, similar to results observed in a previous
study [11], no effect of P2Y12 and P2Y1 blockade was observed for
GPIIb/IIIa activation and platelet-ECC adhesion.
Jackson et al. have reported the platelet PI3K p110b isoform as
important target for new antithrombotic agents, since it plays
a major role in shear-induced activation of platelets [45]. In order
to inhibit the platelet PI3K isoform p110b, TGX-221, an
experimental compound with a reported 1.000-fold selectivity
over the two other PI3K isoforms p110a and p110c [45], was
used. Only the combined administration of P2Y blockade and
PI3K p110b inhibition prevented platelet-ECC adhesion during
hypothermic ECC and provided a better protection of platelet
counts and inhibition of GPIIb/IIIa activation then P2Y blockers
or TGX-221 alone.
Overall, combined blockade of P2Y12, P2Y1 and PI3K p110b
during hypothermic ECC in our current experiments resulted in
an effective reduction of all investigated platelet activation
markers. Furthermore, the effect of combined blockade of
P2Y12, P2Y1 and PI3K p110b achieved inhibitory effects close to
values measured at baseline before ECC and is therefore more
profound then the sole inhibition of P2Y12, P2Y1 or PI3K p110b.
This confirms that activation processes mediated via ADP and
shear stress in combination are the major players for the induction
of platelet activation during hypothermic ECC. Therefore,
inhibition of the respective receptors and activation pathways
may be very beneficial for patients undergoing hypothermic ECC.
As a consequence the development of respective agents for use in
clinical applications is highly desirable. Such innovative substances
for administration during ECC and hypothermia should optimally
have a short half-life. In this case platelet inhibition can be
achieved only during the phase of ECC and hypothermia and
platelet function is quickly restored after termination of infusion
after ECC. We have recently demonstrated the functionality of
this innovative pharmacological principle by employing cangrelor
during hypothermic ECC in vivo [11].
In conclusion, our novel findings indicate that hypothermic
ECC-induced platelet activation as well as subsequent events
including aggregate formation and granulocyte activation are
completely inhibited by combined P2Y12, P2Y1 and PI3K p110b
blockade. This therapeutic strategy carries the potential to
effectively protect platelets and to prevent life-threatening
complications like thrombosis, bleeding and systemic inflammation
in the setting of ECC and hypothermia. Hence, our findings
warrant additional studies to further evaluate this new antiplatelet
strategy and to develop innovative reversible antiplatelet agents for
clinical use.
Limitations and Outlook
The Chandler loop ECC model, which was used for the ex vivo
ECC experiments in this study, is a well-established and routinely
used model to analyze effects of ECC and hypothermia on
platelets and other blood components. However, the obtained
results need to be interpreted with caution, since the Chandler
loop model differs in some points from the setting of ECC as
employed in cardiac surgery. In the Chandler loop PVC tubings,
which contain human whole blood, are circulated in a water bath
at a designated temperature. Therefore, human whole blood is
circulated exclusively and continuously over artificial surfaces,
which causes activation of platelets and leukocytes. However, in
the Chandler loop model heart-lung machine components like
oxygenator and roller pumps, which are routinely used during
cardiac surgery, are omitted and therefore shear stress and other
activating effects might be decreased in comparison to what
happens under clinical conditions. Furthermore, no priming
volume is used in the Chandler loop model, which may result in
Figure 5. P2Y12/P2Y1 blockade in combination with TGX-221
prevents upregulation of the Mac-1 receptor on granulocytes.
Granulocyte activation was measured before (‘‘before circ.’’) and
30 minutes after hypothermic ECC in groups treated with PBS (control
group), 2-MeSAMP and MRS2179 (‘‘P2Y block’’; 100 mM each), propylene
glycol (‘‘PG’’, control group), TGX-221 (‘‘TGX’’; 2.2 mM) and a combina-
tion of P2Y block (100 mM each) and PI3K p110b inhibition with TGX-
221 (2.2 mM; ‘‘P2Y block + TGX’’;). Mac-1 expression on granulocytes was
evaluated using geometric mean values of antibody fluorescence in
flow cytometry. Data are given as means (n = 6) and SD; groups were
compared using RM-ANOVA with Bonferroni’s multiple comparison test;
*p,0.05; ***p,0.001.
doi:10.1371/journal.pone.0038455.g005
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augmented activating effects. Nevertheless, it has been shown in
previous studies that platelet activation is induced during cardiac
operations employing a heart-lung machine and hypothermia to
a similar extent compared to what we found in our experiments
[1,36,46,47].
Our findings indicate that combined P2Y and PI3K inhibition
has the potential to achieve complete platelet inhibition during
hypothermic ECC and may therefore be very beneficial in the
clinical situation. Therefore, our final aim is to evaluate this
antiplatelet strategy in a carefully designed clinical study.
However, previous studies employing different animal models
revealed that there is a species-dependent variation regarding the
effect of TGX-221 on bleeding [45,48]. Therefore, before a clinical
investigation may be initiated, the effect of our experimental
strategy on the bleeding time needs to be carefully evaluated in
human blood. Especially administration of short-acting drugs like
cangrelor or drugs, which don`t influence the bleeding time, will be
the agents of choice for the in vivo setting and should be further
evaluated in the future.
Methods
Blood Sampling
All blood sampling procedures were approved by the Research
and Ethics Unit of the University of Tu¨bingen, Germany (project
number 270/2010BO1). Written informed consent was obtained
from all subjects before blood sampling.
Blood from healthy donors was collected by venipuncture and
anticoagulated with heparin [final concentration (fc): 3 I.U./ml].
All subjects were free of platelet-affecting drugs for at least 14 days.
In vitro Evaluation of Different Concentrations of 2-
MeSAMP and TGX-221
Heparinized humanwhole blood (n= 4)was treated for 5 minutes
at 37uC with the following agents: PBS as control (Invitrogen
GmbH, Karlsruhe, Germany), 2-MeSAMP (fc: 10 and 100 mM;
dissolved in PBS; Sigma-Aldrich Corporation, St. Louis, USA),
a combination of 2-MeSAMP and MRS2179 (fc: 100 mM each;
dissolved in PBS; Tocris Biosciences, Bristol, UK), propylene glycol
(PG; Carl Roth GmbH + Co. KG, Karlsruhe, Germany) as control
or TGX-221 (fc: 0.5 or 2.2 mM; dissolved in PG; Merck Chemicals
Ltd., Nottingham,UK). Afterwards whole bloodwas incubatedwith
Figure 6. Overview of a pharmacological strategy for platelet protection during hypothermic ECC employing P2Y12 and P2Y1
receptor blockers as well as a PI3K p110b inhibitor.
doi:10.1371/journal.pone.0038455.g006
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ADP (fc: 20 mM) and a phycoerythrin (PE)-labeled anti-P-selectin
monoclonal antibody (mAb) (BD Biosciences, Heidelberg, Ger-
many) as well as an fluorescein isothiocyanate (FITC)-labeled anti-
GPIIb mAb (Beckman Coulter, Marseille, France) according to
previously described methods for 20 minutes at 37uC [3]. Next, all
samples were fixed using CellFixH (BD Biosciences) and flow
cytometric analysis was performed within 6 hours.
Ex vivo ECC Chandler Loop Model
In each experiment, baseline values were measured directly
after blood sampling in 20 ml of heparinized blood. A well-
established closed-loop ECC model (Chandler loop) [17] and PVC
tubings (tubing length: 50 cm, inner diameter: 7,6 mm; wall:
2,3 mm) without additional coating (Jostra, Hirrlingen, Germany)
were used to simulate ECC at 28uC. For each donor, five tubings
were filled with 20 ml of fresh heparinized whole blood and
treated with the following agents: the first and second sub-samples
were treated with PBS and PG as controls, respectively. In the
third sub-sample, both platelet ADP receptors were blocked (‘‘P2Y
block’’) employing the experimental P2Y12 antagonist 2-MeSAMP
(fc: 100 mM) and the experimental P2Y1 antagonist MRS2179 (fc:
100 mM). In the fourth sub-sample, PI3K p110b was inhibited by
TGX-221 (fc: 2.2 mM). In the last sub-sample, a combination of
P2Y blockade and PI3K p110b inhibition was employed.
Afterwards, each tubing was closed into a circuit and circulated
in a water bath (at 30 rpm) at 28uC for 30 minutes.
In this study, blood was anticoagulated with heparin, because
heparin is routinely applied during clinical procedures employing
ECCas anticoagulant to prevent activation of plasmatic coagulation
during ECC. The degree of potential platelet activating effects of
heparin on platelets has been analyzed in a previous study and found
to be of minor extent in our ex vivo ECC model [3].
Flow Cytometric Analyses of Blood Samples Before and
After ECC
Analyses of human platelets and granulocytes were performed
directly after blood sampling (‘‘before circulation’’) and after ex vivo
ECC in all treatment groups. Expression of P-selectin, GPIba as
well as binding of the PAC-1 mAb against activated GPIIb/IIIa
on platelets was measured according to previously described
methods [3,10].
Expression of the GPIIb/IIIa receptor on platelets as well as
platelet von Willebrand factor (vWF) binding was evaluated in
25 ml of diluted whole blood (1:50 dilution in modified Tyrode`s
buffer) using 5 ml of an anti-GPIIb-FITC (Beckman Coulter) and
5 ml of an anti-vWF-FITC mAb (1:10 dilution; Abcam, Cam-
bridge, UK), respectively. P-selectin and GPIba expression as well
as vWF binding were also analyzed on ADP-activated (fc: 20 mM)
platelets before and after hypothermic ECC in the PBS group as
positive controls.
Analysis of platelet microparticles (PMPs) was performed after
flow cytometric calibration and setup using a forward scatter/
sideward scatter dot plot and 1 and 3 mm-sized latex beads
(Polysciences, Eppelheim, Germany). PMPs are defined as objects
with a size of #1 mm. The number of PMPs was counted and P-
selectin expression was analyzed as described previously [3].
Platelet-granulocyte aggregates were detected in 25 ml of whole
blood, which was incubated for 20 minutes with 5 ml of an anti-
GPIIb-FITC mAb and 5 ml of an anti-CD15-PE mAb. After-
wards, samples were treated with FACS Lysing Solution (BD
Biosciences) to lyse erythrocytes, centrifuged at 200 g for
5 minutes and washed with PBS.
CellFixH (BD Biosciences) was used for sample fixation. Flow
cytometry was performed within 6 hours using a FACScanH
cytometer (BD Biosciences) according to standard procedures
[3,18].
For evaluation of granulocyte activation, 90 ml of whole blood
was incubated with 10 ml of an anti-CD11b-PE mAb (Beckman
Coulter) for 20 minutes at 37uC, treated with FACS Lysing
Solution, centrifuged at 200 g for 5 minutes and afterwards
washed with PBS. All samples were fixed using CellFixH. Within 6
hours after antibody staining, granulocytes were identified
according to their size and granularity and analyzed using flow
cytometry.
For all samples, suitable isotype antibodies were used to adjust
fluorescence amplification settings. A total of 10.000 events were
acquired in each sample. If not otherwise indicated, geometric
mean fluorescence intensities were used for analyses of flow
cytometric data.
Detection of Platelet Adhesion to the ECC Surface
Platelet adhesion to the ECC surface was detected using
a specially designed enzyme-linked immunosorbent assay (ELISA)
method as previously described [4]. Briefly, ECC tubings were
washed and blocked after circulation and surface-bound GPIIb
was detected employing a primary anti-GPIIb antibody (Sigma,
Deisenhofen, Germany) and an alkaline phosphatase conjugated
secondary antibody (Immunotech/Coulter, Marseille, France).
The chromogenic reaction was stopped by addition of NaOH.
Light absorbance was determined with an ELISA reader MR
5000 (Dynatech, Denkendorf, Germany) at 405 nm.
Analysis of Platelet Counts
Before and after circulation, human whole blood was antic-
oagulated with EDTA (EDTA-MonovetteH, Sarstedt, Nu¨mbrecht,
Germany) for platelet count analysis using an ABX Micros 60
blood analyzer (Axon Lab AG, Baden-Da¨ttwil, Switzerland).
Statistical Analysis
Data are depicted as means with standard deviation (SD). In
order to test data sets for normality, the Kolmogorov-Smirnov test
was performed. Normally distributed data were then analyzed
using repeated measures (RM) ANOVA with Bonferroni’s
multiple comparison test to analyze differences between groups,
while not normally distributed data were analyzed using a non-
parametrical test (Friedman test with Dunn`s multiple comparison
test). All analyses were performed using the statistical software
program GraphPad Prism (version 5, GraphPad Software, La
Jolla, USA). Statistical significance was defined as p,0.05.
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